Organicell Regenerative Medicine, Inc. is a clinical‐stage biotechnology company dedicated to the development and commercialization of cell and exosome‐based therapeutics for a variety of inflammatory and degenerative medical conditions. Leveraging its proprietary placental and amniotic tissue–derived platform, the company isolates and purifies extracellular vesicles (EVs) and mesenchymal‐like cells, which are studied for their ability to modulate immune response and promote tissue repair. With an emphasis on regenerative medicine, Organicell’s research efforts aim to translate novel biologics into scalable treatments.
The company’s pipeline is anchored by exosome‐centered product candidates that target pulmonary, ophthalmic, and musculoskeletal indications. In preclinical and early clinical studies, Organicell’s EV preparations have demonstrated anti‐inflammatory and healing properties, leading to ongoing investigations in respiratory distress and other acute inflammatory conditions. In addition to respiratory health, the company is exploring potential applications in dermatology, wound repair, and orthopedic recovery, with the aim of addressing large unmet medical needs.
Headquartered in Broward County, Florida, Organicell maintains laboratory and manufacturing operations designed to support process development, scale‐up, and regulatory compliance for its biologics platform. The company collaborates with research institutions and clinical sites across the United States to advance its pipeline through regulatory milestones. As a publicly traded entity on the OTC market, Organicell Regenerative Medicine continues to build its platform with the long‐term goal of delivering innovative regenerative therapies to patients and healthcare providers.
AI Generated. May Contain Errors.
